ProofPilot is launching its next-gen platform that makes it as easy to design and run large scale research studies and randomized controlled trials.

The company’s solution is made to address the $25 billion research industry sector with a $100 billion serviceable market. It can run full-scale randomized controlled trials and longitudinal outcome studies without the need for any developers, designers or IT services. Also, by lowering the barrier to getting a study off the ground, ProofPilot allows researchers the ability to rapidly iterate on breakthroughs that can improve the human condition.

Researchers using ProofPilot can design studies that pull in information from hundreds of validated measures, electronic medical records, connected health devices as well as recruit, engage and retain participants with a first-class experience. Interested participants on their end are able to browse research studies, easily contribute to breakthroughs, earn rewards for completing study tasks and learn about new prevention, wellness and health optimization techniques.

“I got into the research industry when I began working on HIV prevention studies doing recruiting, marketing and participant engagement. I became increasingly frustrated that insightful health and social innovations were getting lost because it was too expensive to test whether it really worked,” ProofPilot founder Matthew Amsden said in a statement. “I knew there had to be a more efficient way to do research studies, so my colleagues and I created ProofPilot to bring forth a renaissance in evidence based knowledge that can make a measurable impact on personal and societal health.”

Each year, there are just over 25,000 registered clinical trials per year, and 97% do not end on time. More than 50% of medical treatments conducted by the US have no evidence and there’s billions being spent on solutions with no return on investment.

ProofPilot has worked in conjunction with John Hopkins, Huffington Post, Centers for Disease Control and Prevention (CDC), NYC Health, AIDS Clinical Trials Group (ACTG), UCONN, UCSF School of Medicine, Georgia State University, Southwestern Medical Center and others.